More on KYMR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-35.1% Growth)
- Ratings (8.7 Score)
- Holders

Upcoming Events

- Earnings (10/29/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kymera Therapeutics (NQ:KYMR)
Delayed: 104.78 -3.36 (3.11%)
Prev. Close $108.14  
Open$108.19 
52 Wk High$ 
52 Wk Low$ 
Day High$108.59 
Day Low$104.39 
P/E N/A  
EPS$ 
Volume489,326 

Friends, Peers and Foes (?): BIIB, DYN, GILD, XENE, ACAD (more...)

Oct 8, 2026 04:52 PM Raymond James Starts Kymera Therapeutics (KYMR) at Outperform
Oct 5, 2026 06:57 AM Citi reiterates buy rating on Nektar Therapeutics with $151 target
Oct 5, 2026 05:24 AM Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)
Oct 5, 2026 05:03 AM Kymera Therapeutics (KYMR) PT Raised to $150 at Citi
Oct 1, 2026 05:20 PM Form 4 Kymera Therapeutics, For: Oct 01 Filed by: Mainolfi Nello
Oct 1, 2026 04:10 PM Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello
Oct 1, 2026 06:30 AM Wells Fargo names 13 stocks as overweight tactical ideas
Oct 1, 2026 05:06 AM B.Riley Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Sep 24, 2026 05:36 AM Goldman Sachs Resumes Kymera Therapeutics (KYMR) at Early-Stage Biotech
Sep 23, 2026 08:41 AM Piper Sandler on Kymera Therapeutics (KYMR): 'All Eyes on BroADen2 Data in 4Q'
View All Articles

Entities mentioned with KYMR

View All Entities